###### Abstract  
Background: Since right heart catheterization is rarely performed in patients with severe aortic valve stenosis (AS), echocardiography is currently the tool of choice to determine the presence or absence of pulmonary hypertension (PH). The systolic pulmonary artery pressure (sPAP) has established itself as a reliable measurement value for this purpose. The aim of our study was to evaluate the behavior of plasma-level concentrations of novel cardiovascular biomarkers (sT2, GDF-15, H-FABP, IGF-BP2, and suPAR) in patients with severe AS and an sPAP < 40 mmHg in comparison to patients with an sPAP \(\geq\) 40 mmHg before transcatheter aortic valve replacement (TAVR) and after TAVR (24 h, 96 h, 3 months, and 12 months).  
Methods: We retrospectively separated 85 patients with echocardiographic evidence of severe AS before TAVR procedure into two groups based on sPAP level. An sPAP of 40 mmHg was considered the cut-off value, with the absence of PH defined by an sPAP < 40 mmHg (\(n\) = 32) and the presence of PH defined by an sPAP \(\geq\) 40 mmHg (\(n\) = 53). Blood samples were drawn from each patient one day before TAVR and 24 h, 96 h, 3 months, and 12 months after TAVR. Plasma concentrations of the cardiovascular biomarkers sT2, GDF-15, H-FABP, IGF-BP2, and suPAR were determined and analyzed with univariate and multivariate binary logistic regression and AUROC curves. Results: Patients with severe AS and an sPAP \(\geq\) 40 mmHg had significantly higher plasma concentrations of H-FABP (baseline: \(p\) = 0.022; 24 h: \(p\) = 0.012; 96 h: \(p\) = 0.030; 3 months: \(p\) = 0.006; 12 months: \(p\) = 0.030) and IGF-BP2 (baseline: \(p\) = 0.029; 24 h: \(p\) = 0.012; 96 h: \(p\) = 0.001; 3 months: \(p\) = 0.015; 12 months: \(p\) = 0.022) before and continuously up to 12 months after TAVR than did patients with an sPAP < 40 mmHg sT2, with the exception of the 12-month follow-up. We also consistently found significantly higher plasma concentrations in the sPAP \(\geq\) 40 mmHg group baseline: \(p\) = 0.007; 24 h: \(p\) = 0.006; 96 h: \(p\) = 0.014; 3 months: \(p\) \(\leq\) 0.001; 12 months: \(p\) = 0.092), whereas suPAR had significantly elevated values at baseline and after 24 h in patients with echocardiographic evidence of PH and significantly decreased values after 3 months (baseline: \(p\) = 0.003; 24 h \(p\) = 0.041; 96 h: \(p\) = 0.127; 3 months: \(p\) = 0.006; 12 months: \(p\) = 0.477). Plasma concentrations of GDF-15 were only significantly different after 24 h (baseline: \(p\) = 0.075; 24 h: \(p\) = 0.016; 96 h: \(p\) = 0.101; 3 months: \(p\) = 0.244; 12 months: \(p\) = 0.090). In a multivariate binary logistic regression, atrial fibrillation, tricuspid annular plane systolic excursion (TAPSE), and sT2 at baseline were found to have a significant \(p\)-value < 0.050. Conclusion: In this descriptive study, sT2, H-FABP, and IGF-BP2 emerged as the cardiovascular biomarkers with the greatest potential with respect to echocardiographyPH detection in long-term follow-up after TAVR, as patients with an sPAP \(\geq\) 40 mmHg had significantly continuously higher plasma biomarker concentrations than the corresponding cohort did, with an sPAP < 40 mmHg.  
aortic valve stenosis; biomarker; pulmonary hypertension; systolic; pulmonary artery pressure